Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Conditions:   Head and Neck Squamous Cell Cancer;   Recurrent Head and Neck Squamous Cell Cancer;   Metastatic Head and Neck Squamous Cell Cancer
Interventions:   Drug: Cabozantinib;   Drug: Cetuximab
Sponsor:   Memorial Sloan Kettering Cancer Center
Recruiting

https://ift.tt/2NIGPvL